Exercise-training Before Coronary Artery Bypass Graft (CABG)

This study is currently recruiting participants. (see Contacts and Locations)
Verified August 2014 by Norwegian University of Science and Technology
Sponsor:
Information provided by (Responsible Party):
Norwegian University of Science and Technology
ClinicalTrials.gov Identifier:
NCT00218985
First received: September 20, 2005
Last updated: August 11, 2014
Last verified: August 2014
  Purpose

The aim is to evaluate the effect of exercise training upon endothelial function in the mammary artery of patients who are scheduled for CABG, as well as study the functional properties of single cells isolated from a small biopsy of the left ventricle obtained during surgery.


Condition Intervention
Angina
Coronary Artery Disease
Behavioral: Exercise training

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Single Blind (Investigator)
Primary Purpose: Basic Science
Official Title: Exercise-training Before Coronary Artery Bypass Graft (CABG)

Resource links provided by NLM:


Further study details as provided by Norwegian University of Science and Technology:

Primary Outcome Measures:
  • Cardiovascular function and quality of life [ Time Frame: Before and up to 1 year after intervention ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Structure and function of cardiomyocytes [ Time Frame: After the intervention period ] [ Designated as safety issue: No ]
  • Cardiomyocyte structure and function [ Time Frame: after the intervention period ] [ Designated as safety issue: No ]

Estimated Enrollment: 40
Study Start Date: January 2005
Estimated Study Completion Date: December 2015
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: exercise training Behavioral: Exercise training
Intensity controlled exercise training before the scheduled bypass surgery
No Intervention: physician's advice
patients follow their physician's advice in regard to physical activity.

  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Scheduled for CABG both with and without heart failure

Exclusion Criteria:

  • Unstable angina
  • Unable to walk on a treadmill (except those with heart failure who only will serve as a reference group)
  • Participation in another study
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00218985

Contacts
Contact: Ulrik Wisloff, Ph.D +4773598621 ulrik.wisloff@ntnu.no
Contact: Øyvind Ellingsen, Ph.D, MD oyvind.ellingsen@ntnu.no

Locations
Norway
Norwegian University of Science and Technology Recruiting
Trondheim, Norway, 7489
Contact: Ulrik Wisloff, Ph.D       ulrik.wisloff@ntnu.no   
Principal Investigator: Ulrik Wisloff, Ph.D         
Sponsors and Collaborators
Norwegian University of Science and Technology
Investigators
Principal Investigator: Ulrik Wisloff, Ph.D Norwegian University of Science and Technology
  More Information

No publications provided

Responsible Party: Norwegian University of Science and Technology
ClinicalTrials.gov Identifier: NCT00218985     History of Changes
Other Study ID Numbers: TRIM 158-04
Study First Received: September 20, 2005
Last Updated: August 11, 2014
Health Authority: Norway: Norwegian Social Science Data Services

Keywords provided by Norwegian University of Science and Technology:
Aerobic capacity
Exercise training
CABG
Endothelial function

Additional relevant MeSH terms:
Coronary Artery Disease
Myocardial Ischemia
Coronary Disease
Heart Diseases
Cardiovascular Diseases
Arteriosclerosis
Arterial Occlusive Diseases
Vascular Diseases

ClinicalTrials.gov processed this record on September 18, 2014